Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Digital BiomarkersMarket Summary, 2021
Chapter 3 Digital Biomarkers Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Digital Biomarkers Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
3.3.1.3 Expanding Therapeutic Area Application
3.3.1.4 Increasing Investment in Decentralized Clinical Trials
3.3.2 Market Restraints Analysis
3.3.2.1 Concerns about Data Privacy
3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
3.4 Digital Biomarkers Market Analysis Tools: Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Threat Of Substitutes
3.4.4 Threat Of New Entrants
3.4.5 Competitive Rivalry
3.5 Pestel Analysis
3.5.1 Political & Legal Landscape
3.5.2 Social Landscape
3.5.3 Technology Landscape
3.5.4 Environmental Analysis
3.6 Regulatory Framework
3.7 Technology Overview
3.8 Pricing Analysis
3.9 Covid-19 Impact Analysis
3.9.1 Current And Future Impact Analysis
3.9.2 Impact Of Covid-19 On Market Players
Chapter 4 Competitive Landscape
4.1 Market participation categorization
4.2 Public Companies
4.2.1 Company Market Position Analysis
4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
4.3 Detailed list of market players
Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 – 2030 (USD Million)
5.1 Type Movement Analysis, 2021 & 2030
5.1.1 Wearable
5.1.1.1 Wearable Market Estimates and Forecasts, 2017 – 2030 (Million)
5.1.2 Mobile Based Applications
5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 – 2030 (Million)
5.1.3 Sensors
5.1.3.1 Sensors Market Estimates and Forecasts, 2017 – 2030 (Million)
5.1.4 Others
5.1.4.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 – 2030 (USD Million)
6.1 Clinical Practice Movement Analysis, 2021 & 2030
6.1.1 Diagnostic Digital Biomarkers
6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
6.1.2 Monitoring Digital Biomarkers
6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
6.1.3 Predictive and Prognostic Digital Biomarkers
6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 – 2030 (USD Million)
7.1 Therapeutic Area Movement Analysis, 2021 & 2030
7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.2 Respiratory Disorders
7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.3 Psychiatric Disorders
7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.4 Sleep & Movement Disease
7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.5 Neurological Disorders
7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.6 Musculoskeletal Disorders
7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.7 Others
7.1.7.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 – 2030 (USD Million)
8.1 End-Use Movement Analysis, 2021 & 2030
8.1.1 Healthcare Companies
8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 – 2030 (Million)
8.1.2 Healthcare Providers
8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 – 2030 (Million)
8.1.3 Payers
8.1.3.1 Payers Market Estimates and Forecasts, 2017 – 2030 (Million)
8.1.4 Others
8.1.4.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 – 2030 (USD Million)
9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
9.2 North America
9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.2.2 U.S.
9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.2.3 Canada
9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
9.3 Europe
9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.2 U.K.
9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.3 Germany
9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.4 Netherlands
9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.5 Italy
9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.6 Switzerland
9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.2 Japan
9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.3 China
9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.4 Australia
9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.5 India
9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.6 South Korea
9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.5 Latin America
9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.5.2 Brazil
9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.5.3 Mexico
9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.6 MEA
9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.6.2 South Africa
9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.6.3 Israel
9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 10 Company Profiles
10.1 ActiGraph LLC
10.1.1 Company Overview
10.1.2 Financial Performance
10.1.3 Product Benchmarking
10.1.4 Strategic Initiatives
10.2 AliveCor Inc
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Product Benchmarking
10.2.4 Strategic Initiatives
10.3 Koneksa
10.3.1 Company Overview
10.3.2 Financial Performance
10.3.3 Product Benchmarking
10.3.4 Strategic Initiatives
10.4 Amgen Inc.
10.4.1 Company Overview
10.4.2 Financial Performance
10.4.3 Product Benchmarking
10.4.4 Strategic Initiatives
10.5 Biogen Inc.
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Product Benchmarking
10.5.4 Strategic Initiatives
10.6 Altoida Inc
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Product Benchmarking
10.6.4 Strategic Initiatives
10.7 IXICO plc
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Product Benchmarking
10.7.4 Strategic Initiatives
10.8 Adherium Limited
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Product Benchmarking
10.8.4 Strategic Initiatives
10.9 Empatica Inc
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Product Benchmarking
10.9.4 Strategic Initiatives
10.10 Huma
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Product Benchmarking
10.10.4 Strategic Initiatives
10.11 VivoSense
10.11.1 Company Overview
10.11.2 Financial Performance
10.11.3 Product Benchmarking
10.11.4 Strategic Initiatives
10.12 ResApp (Pfizer)
10.12.1 Company Overview
10.12.2 Financial Performance
10.12.3 Product Benchmarking
10.12.4 Strategic Initiatives